{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:19:26Z","timestamp":1787163566473,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s10549-023-06957-5","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T16:01:22Z","timestamp":1683561682000},"page":"85-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Social determinants of health and CDK4\/6 inhibitor use and outcomes among patients with metastatic breast cancer"],"prefix":"10.1007","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6707-603X","authenticated-orcid":false,"given":"Claire","family":"Sathe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa K.","family":"Accordino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"DeStephano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn L.","family":"Hershman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"issue":"6","key":"6957_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Sung H, Miller KD et al (2022) Breast cancer statistics, 2022. CA Cancer J Clin 72(6):524\u2013541. https:\/\/doi.org\/10.3322\/caac.21754","journal-title":"CA Cancer J Clin"},{"key":"6957_CR2","doi-asserted-by":"publisher","first-page":"107497","DOI":"10.1155\/2011\/107497","volume":"2011","author":"GK Singh","year":"2011","unstructured":"Singh GK, Williams SD, Siahpush M, Mulhollen A (2011) Socioeconomic, rural-urban, and racial inequalities in US cancer mortality: part I-all cancers and lung cancer and part II-colorectal, prostate, breast, and cervical cancers. J Cancer Epidemiol 2011:107497. https:\/\/doi.org\/10.1155\/2011\/107497","journal-title":"J Cancer Epidemiol"},{"issue":"1","key":"6957_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10549-018-4956-y","volume":"173","author":"JX Ren","year":"2019","unstructured":"Ren JX, Gong Y, Ling H, Hu X, Shao ZM (2019) Racial\/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics. Breast Cancer Res Treat 173(1):225\u2013237. https:\/\/doi.org\/10.1007\/s10549-018-4956-y","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"6957_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10549-016-3875-z","volume":"158","author":"C Leopold","year":"2016","unstructured":"Leopold C, Wagner AK, Zhang F et al (2016) Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer. Breast Cancer Res Treat 158(2):333\u2013340. https:\/\/doi.org\/10.1007\/s10549-016-3875-z","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"6957_CR5","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1607303","journal-title":"N Engl J Med"},{"issue":"10","key":"6957_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA et al (2022) Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 386(10):942\u2013950. https:\/\/doi.org\/10.1056\/NEJMoa2114663","journal-title":"N Engl J Med"},{"issue":"32","key":"6957_CR7","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M et al (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35(32):3638\u20133646. https:\/\/doi.org\/10.1200\/JCO.2017.75.6155","journal-title":"J Clin Oncol"},{"key":"6957_CR8","unstructured":"National Comprehensive Cancer Network (2022) NCCN Guidelines. Breast cancer (version 4)"},{"issue":"17","key":"6957_CR9","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1200\/JCO.2015.65.8716","volume":"34","author":"K Reeder-Hayes","year":"2016","unstructured":"Reeder-Hayes K, Peacock Hinton S, Meng K, Carey LA, Dusetzina SB (2016) Disparities in use of human epidermal growth hormone receptor 2-targeted therapy for early-stage breast cancer. J Clin Oncol 34(17):2003\u20132009. https:\/\/doi.org\/10.1200\/JCO.2015.65.8716","journal-title":"J Clin Oncol"},{"issue":"1","key":"6957_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-017-4490-3","volume":"167","author":"MS Dreyer","year":"2018","unstructured":"Dreyer MS, Nattinger AB, McGinley EL, Pezzin LE (2018) Socioeconomic status and breast cancer treatment. Breast Cancer Res Treat 167(1):1\u20138. https:\/\/doi.org\/10.1007\/s10549-017-4490-3","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"6957_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1200\/JCO.2011.36.8399","volume":"30","author":"XC Wu","year":"2012","unstructured":"Wu XC, Lund MJ, Kimmick GG et al (2012) Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 30(2):142\u2013150. https:\/\/doi.org\/10.1200\/JCO.2011.36.8399","journal-title":"J Clin Oncol"},{"issue":"1","key":"6957_CR12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12916-020-01753-0","volume":"18","author":"RP Norris","year":"2020","unstructured":"Norris RP, Dew R, Sharp L et al (2020) Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis. BMC Med 18(1):282. https:\/\/doi.org\/10.1186\/s12916-020-01753-0","journal-title":"BMC Med"},{"issue":"18","key":"6957_CR13","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738\u20131748. https:\/\/doi.org\/10.1056\/NEJMoa1609709","journal-title":"N Engl J Med"},{"issue":"1","key":"6957_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10549-022-06701-5","volume":"196","author":"KD Whitaker","year":"2022","unstructured":"Whitaker KD, Wang X, Ascha M et al (2022) Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer. Breast Cancer Res Treat 196(1):163\u2013173. https:\/\/doi.org\/10.1007\/s10549-022-06701-5","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"6957_CR15","doi-asserted-by":"publisher","first-page":"e213177","DOI":"10.1001\/jamahealthforum.2021.3177","volume":"2","author":"RE Sachs","year":"2021","unstructured":"Sachs RE, Gavulic KA, Donohue JM, Dusetzina SB (2021) Recent trends in medicaid spending and use of drugs with US Food and Drug Administration accelerated approval. JAMA Health Forum 2(10):e213177. https:\/\/doi.org\/10.1001\/jamahealthforum.2021.3177","journal-title":"JAMA Health Forum"},{"issue":"1 Pt 2","key":"6957_CR16","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1475-6773.2011.01308.x","volume":"47","author":"JT Kullgren","year":"2012","unstructured":"Kullgren JT, McLaughlin CG, Mitra N, Armstrong K (2012) Nonfinancial barriers and access to care for US adults. Health Serv Res 47(1 Pt 2):462\u2013485. https:\/\/doi.org\/10.1111\/j.1475-6773.2011.01308.x","journal-title":"Health Serv Res"},{"issue":"7","key":"6957_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.6004\/jnccn.2016.0088","volume":"14","author":"EA Nardi","year":"2016","unstructured":"Nardi EA, Wolfson JA, Rosen ST et al (2016) Value, access, and cost of cancer care delivery at academic cancer centers. J Natl Compr Canc Netw 14(7):837\u2013847. https:\/\/doi.org\/10.6004\/jnccn.2016.0088","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"6957_CR18","doi-asserted-by":"publisher","first-page":"e2015656","DOI":"10.1001\/jamanetworkopen.2020.15656","volume":"3","author":"JT Moyers","year":"2020","unstructured":"Moyers JT, Patel A, Shih W, Nagaraj G (2020) Association of sociodemographic factors with immunotherapy receipt for metastatic melanoma in the US. JAMA Netw Open 3(9):e2015656. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.15656","journal-title":"JAMA Netw Open"},{"issue":"10","key":"6957_CR19","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1002\/cam4.1749","volume":"7","author":"Y Lou","year":"2018","unstructured":"Lou Y, Dholaria B, Soyano A et al (2018) Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Med 7(10):4932\u20134942. https:\/\/doi.org\/10.1002\/cam4.1749","journal-title":"Cancer Med"},{"issue":"1","key":"6957_CR20","doi-asserted-by":"publisher","first-page":"e1000360","DOI":"10.1371\/journal.pgen.1000360","volume":"5","author":"D Reich","year":"2009","unstructured":"Reich D, Nalls MA, Kao WH et al (2009) Reduced neutrophil count in people of African descent is due to a regulatory variant in the duffy antigen receptor for chemokines gene. PLoS Genet 5(1):e1000360. https:\/\/doi.org\/10.1371\/journal.pgen.1000360","journal-title":"PLoS Genet"},{"key":"6957_CR21","doi-asserted-by":"publisher","first-page":"100586","DOI":"10.1016\/j.blre.2019.06.003","volume":"37","author":"SA Atallah-Yunes","year":"2019","unstructured":"Atallah-Yunes SA, Ready A, Newburger PE (2019) Benign ethnic neutropenia. Blood Rev 37:100586. https:\/\/doi.org\/10.1016\/j.blre.2019.06.003","journal-title":"Blood Rev"},{"issue":"2","key":"6957_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10549-022-06574-8","volume":"194","author":"A Schreier","year":"2022","unstructured":"Schreier A, Munoz-Arcos L, Alvarez A, Sparano JA, Anampa JD (2022) Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4\/6 inhibitors. Breast Cancer Res Treat 194(2):337\u2013351. https:\/\/doi.org\/10.1007\/s10549-022-06574-8","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6957_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/ejhpharm-2021-003081","volume":"29","author":"M Liu","year":"2022","unstructured":"Liu M, Qi Y, Wang W, Sun X (2022) Toward a better understanding about real-world evidence. Eur J Hosp Pharm 29(1):8\u201311. https:\/\/doi.org\/10.1136\/ejhpharm-2021-003081","journal-title":"Eur J Hosp Pharm"},{"issue":"1","key":"6957_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1158\/1078-0432.CCR-21-2639","volume":"28","author":"B Arondekar","year":"2022","unstructured":"Arondekar B, Duh MS, Bhak RH et al (2022) Real-world evidence in support of oncology product registration: a systematic review of new drug application and biologics license application approvals from 2015\u20132020. Clin Cancer Res 28(1):27\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2639","journal-title":"Clin Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06957-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-06957-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06957-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T15:02:06Z","timestamp":1685199726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-06957-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["6957"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-06957-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"13 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}